Biopharmaceutical company Enveric Biosciences announced today that Gilgamesh Pharmaceuticals has officially withdrawn its post-grant review request for a patent previously filed against Enveric Biosciences.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This development marks a significant achievement for Enveric Biosciences in safeguarding its intellectual property. Patents are core assets for biotechnology companies, and successfully defending them helps protect the value of the company's R&D investments and future market potential. With the withdrawal of the challenge, Enveric Biosciences can now focus more on advancing its pipeline of therapeutics for neuropsychiatric disorders.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Trending news
MoreWheels Up Experience Inc. has filed documents with the U.S. Securities and Exchange Commission (SEC) to register up to 14.8 million shares of common stock for resale by selling shareholders.
Anteris Technologies Global Corp plans to issue up to $250 million in common stock through TD Cowen as the underwriter.
Crypto prices
More
Bitcoin
BTC
$75,947.95
-2.29%
Ethereum
ETH
$2,073.88
-2.93%
Tether USDt
USDT
$0.9989
-0.01%
BNB
BNB
$652.83
-0.79%
XRP
XRP
$1.34
-2.66%
USDC
USDC
$0.9999
+0.02%
Solana
SOL
$85.08
-2.66%
TRON
TRX
$0.3624
-0.37%
Dogecoin
DOGE
$0.1039
-1.59%
Hyperliquid
HYPE
$55.91
-2.69%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now